Comparative bioavailability studies on some brands of ampicillin capsules.

The bioequivalence of two generics of Ampicillin capsules, hitherto untested, were assessed using Penbritin capsules, the innovator's brand, as the reference product. The bioavailability study was carried out in nine healthy volunteers given one capsule (250 mg) of ampicillin in a completely randomized cross-over design. Statistical analysis (ANOVA) of the results indicated that one of the products tested, designated ampicillin (X), was significantly different (p less than 0.05) in its bioavailability compared to Penbritin while the other product, ampicillin (Helm), was not.